G.R. No. 203697 - Interphil Laboratories, Inc. vs. OEP Philippines, Inc.

Case Summary (G.R. No. 203697)

Factual Background

Under the 1998 Manufacturing Agreement, Interphil Laboratories, Inc. agreed to process and package 90- and 120-mg Diltelan capsules for OEP Philippines, Inc. The Agreement required Interphil to follow formulae, processes, standards, techniques and designs furnished by OEP, to obtain approval for packaging materials, and to perform quality control tests as specified by OEP at OEP’s cost. Interphil inspected packaging materials delivered to its plant and charged OEP a packaging materials inspection fee. Between January 1999 and May 2000, Interphil processed multiple batches, sorted, wrapped and boxed the capsules, and delivered the sealed products to OEP for onward delivery to Elan Taiwan.

Packaging Defect and Recall

On August 8, 2000, Elan Taiwan informed OEP that hospitals reported a packaging defect: several 90-mg capsules had been wrapped in foils labeled for 120-mg capsules and boxed in containers labeled for 90-mg capsules. Investigations identified the defective units as belonging to Lot No. 001369 processed by Interphil in April 2000. OEP recalled and destroyed the affected capsules and sought reimbursement from Interphil of P5,183,525.05 for costs and losses arising from the recall and destruction. Interphil refused to pay, and OEP filed suit before the RTC.

Contractual Allocation of Liability

The Agreement expressly placed on Interphil the obligation to prepare and pack products strictly according to OEP’s furnished specifications and to conduct specified tests. Section VI of the Agreement provided that if a batch failed to meet OEP’s processing or packaging standards, Interphil would correct or destroy the batch on OEP’s instructions, and expenses would be for OEP unless the failure was attributable to Interphil’s failure to observe written instructions or negligence. The parties further issued a letter to the Bureau of Food and Drugs stating joint responsibility for quality but allocating liability to Interphil when the cause of defect was manufacturing or packaging and to OEP when the cause was formulae, process or raw materials supplied by OEP.

Trial Court Proceedings and Judgment

The RTC found for OEP Philippines, Inc. after trial. Applying res ipsa loquitur, the trial court concluded that Interphil was negligent in performing its contractual obligations and that OEP’s unilateral destruction of the defective products did not constitute a breach. The RTC awarded P5,183,525.05 as actual damages, P306,648.81 as compensatory damages, P100,000 as exemplary damages, and P50,000 as attorney’s fees. Interphil’s motion for reconsideration was denied on August 20, 2008.

Court of Appeals Ruling

The Court of Appeals affirmed the RTC’s decision. The CA held that the proximate cause of OEP’s injury was Interphil’s erroneous packing of 90-mg capsules in 120-mg foils, an act within Interphil’s exclusive control. The CA found that Interphil failed to detect or rectify the erroneous packaging despite multiple opportunities, rendering further inquiry into OEP’s alleged faults unnecessary. The CA also held that OEP acted in good faith and prudently in recalling and destroying the products to avoid public health risks. Interphil’s motion for reconsideration at the CA was denied on September 26, 2012.

Issues on Review

The Supreme Court distilled three principal issues: (1) whether the petition should be dismissed for Interphil’s alleged failure to serve a copy of the petition on the CA as required by Rule 45; (2) whether Interphil was negligent under the doctrine of res ipsa loquitur; and (3) whether OEP could be held liable for breach of the Agreement by unilaterally destroying the defective products.

Parties’ Contentions

OEP urged dismissal on procedural grounds for the absence of proof of service of the petition on the CA and argued that the petition raised questions of fact beyond the Court’s remit. Substantively, OEP maintained that both lower courts correctly applied res ipsa loquitur and properly held Interphil liable, and that OEP’s recall and destruction fell within its contractual discretion and was undertaken in good faith. Interphil countered that the omission of service was a rectifiable formal lapse, but on the merits claimed that res ipsa loquitur did not apply because Interphil lacked exclusive control over the packaging materials and that the defect resulted from mis-splicing of foils supplied by OEP. Interphil further argued that OEP breached the Agreement by destroying products without giving Interphil the opportunity to rework or rectify and that the destruction contravened DOH regulations governing disposal.

Procedural Ruling on Failure to Serve the Court of Appeals

The Court applied a liberal remedy to Interphil’s admitted failure to serve the CA prior to filing the petition. Citing precedent such as Pagdonsalan v. NLRC and Sunrise Manning Agency, Inc. v. NLRC, the Court treated the omission as an excusable lapse that Interphil cured by later serving a copy on the CA. The Court declined to dismiss the petition on that procedural ground.

Application of res ipsa loquitur

The Court reviewed the elements of res ipsa loquitur as the evidentiary device that permits an inference of negligence when (1) the accident is of such character that it would not have occurred but for negligence, (2) the accident was caused by an instrumentality within the exclusive control of the party charged, and (3) the accident was not due to any voluntary action by the injured party. Relying on the facts established at the trials, the Court concluded that Interphil had exclusive control over the packaging operations and that the erroneous packing was the immediate and proximate cause of OEP’s loss. The Court found no substantial evidence that OEP contributed to the incident. The Court further observed that Interphil had contractual inspection obligations, charged inspection fees, and warranted the condition of the packaging, thereby undermining Interphil’s claim that the defect existed prior to delivery. Absent arbitrariness or grave abuse by the CA in its factual findings, the Court deferred to the concurrent findings of the RTC and CA and affirmed the application of res ipsa loquitur.

OEP’s Unilateral Destruction and culpa contractual

Addressing Interphil’s contention of culpa contractual under Article 1170, the Court recognized that a contractual breach gives rise to liability. The Court nevertheless held that OEP’s unila

Case Syllabus (G.R. No. 203697)

Parties and Procedural Posture

Interphil Laboratories, Inc. was the petitioner below and a contract manufacturer and packer of pharmaceutical products.
OEP Philippines, Inc. was the respondent below and the trader/client that supplied products and packaging materials for processing and sale.
The case arose from Civil Case No. 03-907 in the Regional Trial Court (RTC) of Makati City, Branch 62, and proceeded on appeal to the Court of Appeals in CA-G.R. CV No. 92550.
The Court reviewed the Decision of the Court of Appeals dated October 21, 2011 and its Resolution dated September 26, 2012 by a petition for review on certiorari under Rule 45, Rules of Court.
The Supreme Court affirmed the Court of Appeals decision with modification by imposing interest at six percent per annum on all damages from finality until fully paid.

Key Factual Allegations

Interphil and OEP executed a Manufacturing Agreement in 1998 whereby Interphil agreed to process and package 90- and 120-mg Diltelan capsules for OEP.
OEP supplied the capsules and the printed foils and boxes and Interphil accepted delivery, inspected materials, charged a packaging materials inspection fee, and performed the packaging.
A defect occurred in Lot No. 001369 processed in April 2000 when several 90-mg capsules were wrapped in foils labeled for 120-mg capsules and placed in boxes labeled for 90-mg capsules.
Elan Taiwan, OEP’s client, notified OEP of hospital complaints about the mispackaged capsules, prompting investigation and recall.
OEP recalled and destroyed the affected capsules and claimed P5,183,525.05 for recall and destruction costs and P306,648.81 for lost profits, which Interphil refused to reimburse.

Contract Provisions

The Manufacturing Agreement required OEP to furnish formulae, methods, and specifications and required Interphil to prepare and pack strictly according to those formulae and standards.
The Agreement obligated Interphil to conduct quality control tests specified by OEP at OEP’s expense and prohibited changes in packaging materials without OEP’s prior written approval.
Under Section VI, the Agreement provided that defective batches would be corrected or destroyed on OEP’s instructions and that expenses for correction or destruction would be for OEP’s account unless failure was attributable to Interphil’s negligence.
The parties executed a letter to the Bureau of Food and Drugs stating that they would be jointly responsible for product quality and that liability would be allocated depending on whether the defect was due to manufacturing/packaging or to formulae, methods, or raw materials supplied by OEP.

Issues

Whether the petition to the Supreme Court must be dismissed for Interphil’s failure to timely serve the Court of Appeals with a copy of the petition as required under Rule 45, Rules of Court.
Whether Interphil was negligent in the packaging of the capsules under the doctrine of res ipsa loquitur.
Whether OEP could be held liable for breach of the Agreement for unilaterally recalling and destroying the defectively packaged products.

Contentions of the Parties

OEP argued that the petition should be dismissed for failure of Interphil to prove service of the petition on the Court of Appeals and that the case raised predominantly factual issues beyond the Court’s certiorari review.
OEP also contended that res ipsa loquitur applied because the erroneous packaging occurred within Interphil’s exclusive control and that OEP acted in good faith in recalling and destroying the products to protect public health.
Interphil maint